ABSTRACT
Mimecan belongs to a family of leucine-rich proteoglycans that are secreted into the extracellular matrix. In order to investigate the function of mimecan, the coding region of mimecan was amplifed from a human pituitary cDNA by PCR and the recombinant prokaryotic expression vector pGEX-M was constructed. The vactor was transformed into E.coli BL21(DE3)and the GST-M fusion protein of 38 Kd was ecpressed in the bacteria under induction of IPTG. After purification, the fusion protein was infucted into New Zealand rabbits to prepare polyclonal antibody. The antibody was tested by Western blotting for their specificity and sensitivity. Using the antibody it was found the mimecan was expressed highly in certain types of human pituitary tumor tissues. These results make it possible for studying the biological function of mimecan.
ABSTRACT
OBJECTIVE: To prepare gastroretentive slow- released Tinidazole capsules so that the drug can stay at the stomach and act to infective lesions for a long period of time so as to improve the therapeutic efficacy and reduce the adverse reactions.METHODS: The content of Tinidazole was determined by UV - spectrophotometry, the quality standard was established, the stability was studied, the levels of Tinidazole in saliva were detected with HPLC in human body and in vitro dissolubility and human bioavailability were studied .RESULTS: The capsules were stable in quality.The retentive period in artificial gastric juice has reached lOh and in vitro dissolubility(0.5h - 5h) could be described as zero order dissolution .The bioavailability was 163.6% .CONCLUSION: Gastroretentive slow - released Tinidazole capsule was an effective agent for treating HP - related diseases.